Kiniksa accounting chief sells 36,260 shares

The chief accounting officer's reported sales were made under a Rule 10b5-1 plan adopted July 30, 2026, alongside option exercises at four stated exercise prices.

Available on EDGAR 11/03/2026 - 06:26 PM EST Accepted by SEC EDGAR 11/03/2026 - 06:26 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna exercised options covering 3,932 shares at $11.10, 7,209 at $11.97, 4,689 at $10.76, and 4,065 at $17.76, acquiring the corresponding Class A ordinary shares on October 30, 2026. He also sold 36,260 Class A ordinary shares in seven transactions that day under a Rule 10b5-1 plan adopted July 30, 2026, including 6,030 shares at a weighted-average sale price of $91.87 and 5,350 at $97.74.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 15 txns

Insider Megna Michael R

Role CHIEF ACCOUNTING OFFICER

Sold 36,260 shs ($3.42M)

Approx. gross sale proceeds $3.42M

Approx. exercise cost $253K

Type	Security	Shares	Price	Value
Exercise	Share Option ^{F1, F9}	3,932	$0.00	$0.00
Exercise	Share Option ^{F1, F9}	7,209	$0.00	$0.00
Exercise	Share Option ^{F1, F10}	4,689	$0.00	$0.00
Exercise	Share Option ^{F1, F11}	4,065	$0.00	$0.00
Exercise	Class A Ordinary Share ^F1	4,689	$10.76	$50K
Exercise	Class A Ordinary Share ^F1	3,932	$11.10	$44K
Exercise	Class A Ordinary Share ^F1	7,209	$11.97	$86K
Exercise	Class A Ordinary Share ^F1	4,065	$17.76	$72K
Sale	Class A Ordinary Share ^{F1, F2}	6,030	$91.87	$554K
Sale	Class A Ordinary Share ^{F1, F3}	6,831	$92.77	$634K
Sale	Class A Ordinary Share ^{F1, F4}	9,508	$94.20	$896K
Sale	Class A Ordinary Share ^{F1, F5}	3,705	$94.86	$351K
Sale	Class A Ordinary Share ^{F1, F6}	3,145	$96.08	$302K
Sale	Class A Ordinary Share ^{F1, F7}	1,691	$97.11	$164K
Sale	Class A Ordinary Share ^{F1, F8}	5,350	$97.74	$523K

Holdings After Transaction: Share Option — 19,377 contracts (Direct); Class A Ordinary Share — 12,697 shares (Direct)

Footnotes (11)

F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.275 and $92.26. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.28 and $93.27. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.38. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F7. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F8. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F9. The option is fully vested and exercisable.
F10. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
F11. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

Key Figures

Options exercised: 3,932 shares at $11.10 per share Options exercised: 7,209 shares at $11.97 per share Options exercised: 4,689 shares at $10.76 per share +4 more

7 metrics

Options exercised 3,932 shares at $11.10 per share October 30, 2026

Options exercised 7,209 shares at $11.97 per share October 30, 2026

Options exercised 4,689 shares at $10.76 per share October 30, 2026

Options exercised 4,065 shares at $17.76 per share October 30, 2026

Shares sold 36,260 shares Seven transactions on October 30, 2026

Reported sale 6,030 shares at a weighted-average sale price of $91.87 per share October 30, 2026

Reported sale 5,350 shares at a weighted-average sale price of $97.74 per share October 30, 2026

Key Terms

10b5-1 plan, weighted average sales price, vesting commencement date, fully vested and exercisable

4 terms

10b5-1 plan regulatory

"pursuant to a 10b5-1 plan executed by the reporting person"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

weighted average sales price financial

"reflects a weighted average sales price"

vesting commencement date technical

"The vesting commencement date is April 1, 2023."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable technical

"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did Michael R. Megna sell?

Michael R. Megna, Kiniksa Pharmaceuticals International, plc's chief accounting officer, sold 36,260 Class A ordinary shares on October 30, 2026, in seven transactions under a Rule 10b5-1 plan adopted July 30, 2026. Reported weighted-average sale prices included $91.87 for 6,030 shares and $97.74 for 5,350 shares.

What KNSA options did Michael R. Megna exercise?

On October 30, 2026, Michael R. Megna exercised options covering 3,932 shares at $11.10, 7,209 shares at $11.97, 4,689 shares at $10.76, and 4,065 shares at $17.76. The corresponding Class A ordinary shares were acquired.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last)

(First)

(Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON

W1J 7NJ

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Share	10/30/2026		M⁽¹⁾		4,689	A	$10.76	33,751	D
Class A Ordinary Share	10/30/2026		M⁽¹⁾		3,932	A	$11.1	37,683	D
Class A Ordinary Share	10/30/2026		M⁽¹⁾		7,209	A	$11.97	44,892	D
Class A Ordinary Share	10/30/2026		M⁽¹⁾		4,065	A	$17.76	48,957	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		6,030	D	$91.87⁽²⁾	42,927	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		6,831	D	$92.77⁽³⁾	36,096	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		9,508	D	$94.2⁽⁴⁾	26,588	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		3,705	D	$94.86⁽⁵⁾	22,883	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		3,145	D	$96.08⁽⁶⁾	19,738	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		1,691	D	$97.11⁽⁷⁾	18,047	D
Class A Ordinary Share	10/30/2026		S⁽¹⁾		5,350	D	$97.74⁽⁸⁾	12,697	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option	$11.1	10/30/2026		M⁽¹⁾			3,932	⁽⁹⁾	04/06/2032	Class A Ordinary Share	3,932	$0	0	D
Share Option	$11.97	10/30/2026		M⁽¹⁾			7,209	⁽⁹⁾	08/31/2032	Class A Ordinary Share	7,209	$0	0	D
Share Option	$10.76	10/30/2026		M⁽¹⁾			4,689	⁽¹⁰⁾	03/31/2033	Class A Ordinary Share	4,689	$0	2,983	D
Share Option	$17.76	10/30/2026		M⁽¹⁾			4,065	⁽¹¹⁾	08/31/2033	Class A Ordinary Share	4,065	$0	16,394	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.275 and $92.26. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.28 and $93.27. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.38. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

7. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

8. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

9. The option is fully vested and exercisable.

10. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.

11. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

	/s/ Douglas Barry, Attorney-in-Fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR